Regarding the concern regarding metastatic sites and study populations in previous studies, bevacizumab in combination with 1st-/2nd- EGFR-TKIs would be considered as first-line therapy for metastatic EGFR-mutated NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.